Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | PRKCB | P05771 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCH | P24723 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CTSE | P14091 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26671857 | 0.86 | GPR119 (0.49) | PIK3CAMTORPRKDCGPR119POLB | |
| SCHEMBL2248124 | 0.85 | GPR119 (0.46) | PIK3CAMTORPRKDCGPR119POLB | |
| SCHEMBL3753459 | 0.84 | CYP3A4 (0.46) | PIK3CAMTOROPRD1HSD11B1 | |
| SCHEMBL6160925 | 0.84 | HSD11B1 (0.56) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL2250127 | 0.82 | ALDH1A1 (0.47) | PIK3CAMTORPRKDCGPR119POLB | |
| SCHEMBL2251051 | 0.81 | GPR119 (0.46) | PIK3CAMTORPRKDCGPR119POLB | |
| SCHEMBL12357647 | 0.81 | GPR119 (0.46) | PIK3CAMTORPRKDCGPR119POLB | |
| SCHEMBL13719293 | 0.81 | POLB (0.50) | GPR119POLBDDB1CRBNDTYMK | |
| SCHEMBL27100998 | 0.80 | GPR119 (0.47) | GPR119POLBOPRM1OPRD1OGFRL1 | |
| SCHEMBL29712771 | 0.80 | GPR119 (0.47) | GPR119POLBOPRM1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249833-B1 | PRODRUGS OF CGRP RECEPTOR ANTAGONIST | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8080544-B2 | Prodrugs of CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080544-B2 | Prodrugs of CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080544-B2 | Prodrugs of CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100298269-A1 | PRODRUGS OF CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298269-A1 | PRODRUGS OF CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009100090-A1 | PRODRUGS OF CGRP RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298269-A1 | PRODRUGS OF CGRP RECEPTOR ANTAGONISTS | CALCRL, BDKRB1, BDKRB2 | PIK3CA 2676/4885MTOR 3334/4885PRKDC 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.